Delivery Order SPE2DR25D9133-SPE2DR26FCFW7
Award Date 4/2/26
Potential Completion Date 4/23/26
Potential Value $7.8K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 18, 2026, for Nuplazid 34 mg capsules, with a ceiling value of $3,923.82. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract that authorizes firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide. Place...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 13, 2026, for supply of Nuplazid 34 mg capsules, with a ceiling value of $11,771.46. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 12, 2026, for $11,771.46 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of Nuplazid 34 mg capsules. DMS Pharmaceutical Group Inc. is a woman-owned small business. The parent contract, SPE2DR, is a single-award indefinite delivery contract with a $499.9 million ceiling and ultimate completion date of December 31, 2036, supporting pharmaceutical supply to...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 13, 2026, for $11,771.46 to supply Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables...
- The Defense Logistics Agency issued a $11,771.46 delivery order to DMS Pharmaceutical Group Inc. on February 4, 2026, for Nuplazid 34 mg capsule 30-count units under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 24, 2026, for Nuplazid 34 mg capsules, with a ceiling value of $3,923.82. This delivery order was issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price calls for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations. Place of performance...
- The Defense Logistics Agency issued a $11,771.46 delivery order to DMS Pharmaceutical Group Inc. on April 1, 2026, for Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is placed against the company's single-award IDC under PPV-G GEN V, a $499.999 billion Defense Logistics Agency pharmaceutical supply contract with a completion date of December 31, 2036. The PPV-G GEN V...
- The Defense Logistics Agency issued a $3,923.82 delivery order to DMS Pharmaceutical Group Inc. on March 3, 2026, for Nuplazid 34 mg capsules under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The delivery order is issued under the PPV-G GEN V, a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 24, 2026, for $3,923.82 in firm fixed-price pharmaceutical supply under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract. The order covers Nuplazid 34 mg capsule 30-count units for delivery to Park Ridge, Illinois, with an ultimate completion date of April 14, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that holds a...
- The Defense Logistics Agency issued a $3,925.34 delivery order to DMS Pharmaceutical Group Inc. on April 2, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for NUPLAZID 10 mg tablets (30-count). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. The order is firm fixed price with an ultimate completion date of April 23, 2026. Place of...